How long does azelastine nasal spray remain in the system before allergy testing?

Discontinuation of Azelastine Nasal Spray Before Allergy Testing

Azelastine nasal spray should be discontinued for at least 48 hours (2 days) before allergy skin testing to avoid suppression of the wheal-and-flare response. 1

Evidence-Based Washout Period

The most direct evidence comes from a randomized, double-blind, placebo-controlled study specifically examining this question:

• After 14 days of continuous azelastine nasal spray use (2 sprays per nostril twice daily), the wheal response returned to within 20% of baseline values in 82-88% of patients by 48 hours after discontinuation 1
• Flare responses similarly normalized within 48 hours in 92% of patients 1
• A single dose of azelastine did not significantly suppress the histamine skin test response when tested 5 hours later 1

Pharmacokinetic Considerations

The FDA-approved drug label provides important context for this washout period:

• Elimination half-life: 22 hours for azelastine 2
• Active metabolite (desmethylazelastine) half-life: 54 hours when administered orally 2
• Time to peak plasma concentration: 2-3 hours after intranasal administration 2
• Systemic bioavailability: Approximately 40% after intranasal use 2

Given the 22-hour elimination half-life, approximately 4-5 half-lives (88-110 hours, or roughly 4-5 days) would be needed for near-complete drug elimination. However, the clinical data demonstrates that functional suppression of skin testing resolves more rapidly than complete drug elimination.

Guideline Recommendations for Antihistamine Discontinuation

The 2009 Joint Task Force guidelines on oral food challenge testing provide broader context for antihistamine withdrawal before allergy testing:

• Antihistamine nasal spray: Discontinue 12 hours before testing 3

Important caveat: This 12-hour recommendation from the food challenge guideline 3 conflicts with the specific research data on azelastine showing 48-hour washout is needed 1. The research study is more specific to azelastine and used objective measurements of wheal suppression, making it the more reliable source for this particular medication.

Contrasting Evidence on Lower Doses

One smaller study (n=10) using a lower pediatric dose of azelastine (0.28 mg/dose, or 1 spray per nostril twice daily) found no significant suppression of skin test responses even during active treatment 4. However, this study had important limitations:

• Very small sample size
• Used half the standard adult dose
• Conflicts with the larger, more rigorous study 1

Clinical recommendation: Do not rely on this lower-dose study to justify testing patients on active azelastine therapy, as the standard adult dosing (2 sprays per nostril twice daily) clearly suppresses skin testing 1.

Practical Algorithm for Allergy Testing

For patients on azelastine nasal spray:

1. Discontinue azelastine at least 48 hours (2 days) before skin testing 1
2. Consider extending to 72 hours (3 days) if the patient has been on high-dose therapy or has renal insufficiency (which increases drug exposure by 70-75%) 2
3. Verify the patient has not used the medication within this window before proceeding with testing
4. If urgent testing is needed, consider in vitro specific IgE testing, which is not affected by antihistamine use

Common Pitfalls to Avoid

• Do not rely on the 12-hour washout period cited in general antihistamine guidelines 3, as azelastine-specific data requires 48 hours 1
• Do not assume a single dose won't matter—while one dose may not suppress testing 1, patients on chronic therapy require the full 48-hour washout
• Do not forget to ask about combination products—patients using azelastine/fluticasone (Dymista) still need the 48-hour washout for the azelastine component 2
• Consider renal function—patients with creatinine clearance <50 mL/min have 70-75% higher drug exposure and may benefit from a longer washout period 2